Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 05, 2006. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider trading activity rather than a financial performance report.
Material Changes
The only material change disclosed is a transaction by Mr. R Bondy, who acquired a beneficial interest in 2 Ordinary Shares purchased under a Personal Equity Plan on July 3, 2006, at a price of GBP 15.18 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It strictly details the notification of the share transaction in accordance with Disclosure Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the total number of shares held by Mr. R Bondy following this acquisition.
- Confirm the pricing of the Personal Equity Plan relative to the market price on July 3, 2006.
- Check for any subsequent filings regarding other director transactions for the same period.